X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
anti-pd-l1 antibody (486) 486
index medicus (415) 415
immunotherapy (374) 374
oncology (335) 335
humans (334) 334
cancer (224) 224
safety (175) 175
nivolumab (147) 147
pd-l1 (136) 136
tumors (124) 124
female (122) 122
anti-pd-l1 (118) 118
immunology (114) 114
animals (110) 110
melanoma (100) 100
pembrolizumab (100) 100
chemotherapy (99) 99
care and treatment (94) 94
apoptosis (93) 93
lymphocytes (93) 93
pd-1 (93) 93
male (92) 92
antibodies, monoclonal - therapeutic use (90) 90
ipilimumab (90) 90
open-label (89) 89
b7-h1 antigen - metabolism (87) 87
middle aged (86) 86
t-cells (85) 85
clinical activity (83) 83
immunotherapy - methods (83) 83
pd-1 blockade (83) 83
pd-l1 expression (82) 82
prognosis (81) 81
aged (80) 80
blockade (79) 79
lung cancer (76) 76
immunohistochemistry (74) 74
pd-l1 protein (74) 74
antineoplastic agents - therapeutic use (73) 73
metastasis (73) 73
b7-h1 antigen - antagonists & inhibitors (71) 71
immune checkpoint (71) 71
b7-h1 antigen - immunology (70) 70
expression (70) 70
tumor-infiltrating lymphocytes (69) 69
ligands (67) 67
programmed cell death 1 receptor - antagonists & inhibitors (66) 66
neoplasms - immunology (65) 65
adult (63) 63
t cells (62) 62
cell death (61) 61
biomarkers (59) 59
cell lung-cancer (59) 59
anti-pd-1 (58) 58
cell biology (58) 58
survival (57) 57
cancer therapies (56) 56
mice (55) 55
lymphocytes t (54) 54
pd-1 protein (54) 54
patients (53) 53
programmed cell death 1 receptor - immunology (52) 52
metastatic melanoma (51) 51
therapy (51) 51
treatment outcome (50) 50
antibodies (49) 49
article (49) 49
ctla-4 blockade (49) 49
mutation (49) 49
antigens (48) 48
health aspects (48) 48
review (48) 48
tumor microenvironment (48) 48
clinical trials (47) 47
docetaxel (47) 47
pathology (47) 47
carcinoma (46) 46
medicine, research & experimental (46) 46
research (46) 46
advanced melanoma (44) 44
gene expression (43) 43
lung neoplasms - pathology (43) 43
analysis (42) 42
b7-h1 antigen - genetics (41) 41
drug therapy (41) 41
medical prognosis (41) 41
programmed cell death 1 receptor - metabolism (41) 41
cell line, tumor (40) 40
dendritic cells (40) 40
b7-h1 (39) 39
lung cancer, non-small cell (39) 39
lung neoplasms - drug therapy (39) 39
aged, 80 and over (38) 38
checkpoint blockade (38) 38
pharmacology & pharmacy (38) 38
breast cancer (37) 37
mpdl3280a (37) 37
cytotoxicity (36) 36
immune response (36) 36
multicenter (36) 36
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CANCER RESEARCH, ISSN 0008-5472, 09/2015, Volume 75, Issue 17, pp. 3466 - 3478
A current pressing need in cancer immunology is the development of preclinical model systems that are immunocompetent for the study of human tumors. Here, we... 
IMMUNOSTIMULATORY MONOCLONAL-ANTIBODIES | SURVIVAL | CELLS | RESPONSES | ANTI-PD-L1 ANTIBODY | ONCOLOGY | SAFETY | MOUSE | HOST-DISEASE | BLOCKADE | IPILIMUMAB
Journal Article
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 10/2018, Volume 24, Issue 19, pp. 4820 - 4833
Purpose: Cancer-associated fibroblasts (CAFs) in the tumor microenvironment (TME) play a central role in tumor progression. We investigated whether CAFs can... 
PRIVILEGE | ANTI-PD-L1 ANTIBODY | ONCOLOGY | IMMUNOTHERAPY | ACTIVATION PROTEIN | STROMA | ANTITUMOR IMMUNITY | INFILTRATING LYMPHOCYTES TILS | BLOCKADE | INTERLEUKIN-6 | CARCINOMA
Journal Article
Chest, ISSN 0012-3692, 08/2017, Volume 152, Issue 2, pp. 271 - 281
Programmed death 1 (PD-1) programmed death-ligand 1 (PD-L1) inhibitors show significant clinical activity in non-small cell lung carcinoma (NSCLC). However,... 
non-small cell lung cancer | meta-analysis | pneumonitis | immune-related adverse events | immunotherapy | 1ST-LINE TREATMENT | SAFETY | PHASE-II | OPEN-LABEL | ATEZOLIZUMAB | DOCETAXEL | TRIAL | ANTI-PD-L1 ANTIBODY | RESPIRATORY SYSTEM | NIVOLUMAB | AVELUMAB MSB0010718C | CRITICAL CARE MEDICINE
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 26, pp. 2509 - 2520
Persons with mismatch repair–deficient tumors are more likely than persons with mismatch repair–proficient tumors to benefit from pembrolizumab — which... 
MEDICINE, GENERAL & INTERNAL | COLORECTAL CARCINOMAS | ANTI-PD-L1 ANTIBODY | SAFETY | MICROSATELLITE INSTABILITY | DNA | GERMLINE MUTATIONS | PREDISPOSE | CLINICAL ACTIVITY | CANCER | LYMPHOCYTES | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Colorectal Neoplasms - genetics | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease-Free Survival | Neoplasm Metastasis - genetics | Neoplasm Metastasis - drug therapy | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | DNA Mismatch Repair | Adult | Female | Adenocarcinoma - genetics | Aged | Colorectal Neoplasms - pathology | Antibody diversity | Carcinoma | Genetic disorders | Analysis | Research | Risk factors | Cancer | Tumors | Antigens | Yeast | PD-1 protein | Colorectal carcinoma | Body weight | Colorectal cancer | Autoantigens | DNA repair | Survival | Metastases | Pembrolizumab | Immune checkpoint | Immunogenicity | Mismatch repair | Death | Mutation | Genetic recombination | Cancer therapies | Drug dosages | Immune system | Medical research | Melanoma | Patients | Studies | Hypotheses | Pancreatic cancer | Epigenetics | Biomarkers | Ligands | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 21, pp. 2018 - 2028
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 22, pp. 2108 - 2121
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 908 - 918
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 387, Issue 10027, pp. 1540 - 1550
Summary Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for... 
Internal Medicine | CRITERIA | MEDICINE, GENERAL & INTERNAL | ANTI-PD-L1 ANTIBODY | THERAPY | NSCLC | IMMUNOTHERAPY | PD-L1 | BLOCKADE | NIVOLUMAB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Patient Selection | Taxoids - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Adult | Female | Taxoids - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Lung Neoplasms - chemistry | Docetaxel | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Taxoids - administration & dosage | Aged | B7-H1 Antigen - analysis | Carcinoma, Non-Small-Cell Lung - drug therapy | Antimitotic agents | Medical colleges | Lung cancer, Non-small cell | Antineoplastic agents | Analysis | Chemotherapy | Biopsy | Genes | Lung cancer | Clinical trials | Oncology | Mutation | Tumors | Slopes | Cell survival | Medical treatment | Medical services | FDA approval | Survival | Patients | Medical centres | Pembrolizumab | Randomization | Interactive systems | Immunotherapy | Risk assessment | PD-L1 protein | Biomarkers | Index Medicus | Abridged Index Medicus
Journal Article